July 9, 2002

FOR: ZOLL Medical Corporation

INVESTOR CONTACT: A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
(978) 421-9655
PRESS CONTACT: Robert Minicucci
Corporate Communications Manager
ZOLL Medical Corporation
+1 (978) 421-9832
rminicucci@zoll.com



FOR IMMEDIATE RELEASE

ZOLL PROVIDES GRANT TO HELP ESTABLISH NEW AED INSTRUCTOR FOUNDATION

BURLINGTON, MA  Tuesday, July 09, 2002 – ZOLL Medical Corporation (Nasdaq: ZOLL), a manufacturer of non-invasive cardiac resuscitation devices, today announced that the company has provided an unrestricted educational grant to establish the new AED Instructor Foundation. The Foundation is designed to help initial emergency care instructors provide critical training and support services for CPR and early defibrillation, as well as provide access to a new, affordable automated external defibrillator (AED) specifically designed for laypeople who are likely to be designated responders to victims of sudden cardiac arrest in public gathering places.

"In recent years, AEDs have become more commonplace in large public areas, such as airports, major office buildings and shopping malls, which is an important step forward in saving victims of sudden cardiac arrest," said Richard A. Packer, President and Chief Executive Officer of ZOLL Medical. "ZOLL recognized the serious need to support proper training and access to simple, user-friendly AEDs in places where we live, work and gather and where immediate medical care is not always readily available. With the establishment of the new AED Instructor Foundation, we can help instructors expand AED access to smaller venues, where these lifesaving devices are desperately needed but often not available. ZOLL is very pleased to support the new AED Instructor Foundation’s efforts to broaden needed training and access to emergency rescue capabilities in communities everywhere."

The AED Instructor Foundation will offer Affiliates a variety of services through its web site (www.aedinstructorfoundation.org), including training materials, professional development opportunities and financial support. The Foundation will also give instructors access to AEDs to help make this lifesaving technology available in many more communities. Affiliation with the AED Instructor Foundation will be free and open to anyone engaged in initial emergency care training. Affiliates must have completed prescribed instructor training for a state or nationally approved initial life support and/or AED training program.

ZOLL recently received FDA marketing clearance for its new AED, the ZOLL AED Plus, designed specifically for the first responder and public access market. This first-of-its-kind AED features a combination of simple, step-by-step illustrations and audio coaching, to make a stressful and challenging medical crisis a more manageable and controlled rescue for laypersons assisting victims of sudden cardiac arrest.

AEDs are used to treat sudden cardiac arrest resulting from ventricular fibrillation (VF),a spontaneous, mostly fatal interruption of normal heartbeat and a leading cause of death in the United States. Recent estimates from the Centers for Disease Control and Prevention (CDC) indicate that sudden cardiac death (SCD) takes the lives of approximately 400,000 people each year. According to the American Heart Association (AHA), nearly 49 percent of those who die from sudden cardiac arrest could be saved with public access defibrillation. The AHA states, “Public access defibrillation, which places AEDs in the hands of trained laypersons, has the potential to be the single greatest advance in the treatment of VF cardiac arrest since the development of CPR.”

ZOLL Medical Corporation, headquartered in Burlington, MA, designs, manufactures and markets an integrated line of proprietary, non-invasive resuscitation devices and disposable electrodes. Used by health care professionals to provide both types of cardiac resuscitation – pacing and defibrillation – these products are essential in the emergency treatment of cardiac arrest victims, both inside and outside the hospital. ZOLL also designs and markets software, which automates collection and management of both clinical and non-clinical data for emergency medical service providers. ZOLL has operations in the United States, Canada, United Kingdom, Germany, France, the Netherlands, Australia, and business partners in all of the world’s major markets. For more information about ZOLL and its products, visit the ZOLL web site at www.zoll.com.

Certain statements contained in this press release, including statements regarding the anticipated development of the Company's business, the intent, belief or current expectations of the Company, its directors or its officers, primarily with respect to the Company's business model and future operating performance of the Company, including expectations regarding results in future periods, operating performance and contributions to results from the Company’s new Public Access Defibrillation product, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-Q filed on May 15, 2002, the future performance of the direct sales operations, the outcome of a pending patent infringement suit relating to the ZOLL AED Plus, as well as uncertainties regarding the market, acceptance and profitability of the ZOLL AED Plus, the length and severity of the current economic slowdown and its impact on capital spending budgets, the reduction in overall capital equipment expenditures in the hospital and pre-hospital markets, the potential disruption in the transportation industry on the Company’s supply chain and product distribution channels, and the desire or ability of other parties to purchase the Company's products.

# # #